What's Happening?
Pulse Biosciences has received FDA approval to begin a clinical study of its pulsed field ablation system for treating atrial fibrillation during cardiac surgeries. The NANOCLAMP AF study will enroll up to 136 patients across 20 sites. Meanwhile, Galvanize Therapeutics has raised $100 million to develop pulsed electric field treatments for cancer and lung disease, appointing Doug Godshall as CEO. The funding will support the expansion of Galvanize's Aliya platform for solid tumors and RheOx device for chronic bronchitis.
Why It's Important?
Pulse Biosciences' FDA approval marks a significant step in advancing nonthermal cardiac ablation technology, potentially offering safer and more effective treatment options for atrial fibrillation. Galvanize Therapeutics' funding and leadership change signal a strong commitment to developing innovative treatments for chronic diseases, addressing unmet medical needs. These developments highlight the growing interest and investment in medical technologies that can improve patient outcomes and expand treatment options.
What's Next?
Pulse Biosciences will proceed with the NANOCLAMP AF study, aiming to demonstrate the effectiveness of its cardiac surgical device. Galvanize Therapeutics plans to use the new funding to expand its commercial operations and continue developing its treatment platforms. Both companies are poised to make significant contributions to the medical technology field, potentially leading to new therapeutic options for patients.
